About this trial
This multicenter retrospective study aims to develop, validate, and clinically apply an artificial intelligence (AI)-powered electrocardiography (ECG) algorithm for the diagnosis and prognostic prediction of cardiovascular diseases, including coronary artery disease and heart failure. By utilizing encrypted raw 12-lead ECG text data and deep neural network models, the study evaluates the effectiveness of AI-enhanced ECG in detecting cardiac abnormalities and predicting clinical outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged 19 years or older diagnosed with tachycardias (including PSVT, WPW syndrome, PVC, or VT) who have undergone an electrophysiological study (EPS) and radiofrequency catheter ablation (RFCA).
Patients with 12-lead electrocardiogram (ECG) records extractable as text (XML) files.
Disqualifiers
None
Trial population
Retrospective cohort of patients diagnosed with tachycardias who underwent electrophysiological studies and catheter ablation at participating institutions\[cite: 1\].
Trial design
Cohort
Retrospective
Treatments tested in this trial
AI-based ECG Diagnostic and Localization Algorithm
Diagnostic testApplication of a deep learning-based 12-lead electrocardiogram (ECG) algorithm to analyze raw text data for the differential diagnosis and localization of tachycardias, including PSVT, WPW syndrome, PVC, and VT\[cite: 1\].
Treatment groups
Trial outcomes
Primary outcomes
Diagnostic Performance (AUC-ROC) of AI-ECG Models
Secondary outcomes
Localization Accuracy of Tachycardia Origin Sites
Sponsors and contacts
Click on the lead sponsor to view all of their trials.